Review

Mutational Analysis of Merkel Cell Carcinoma

Derek J. Erstad 1 and James C. Cusack Jr. 2,*

1 Department of Surgery, Massachusetts General Hospital, 55 Fruit Street, Boston, MA 02114, USA; E-Mail: derstad@partners.org
2 Division of Surgical Oncology, Harvard Medical School, Massachusetts General Hospital, 55 Fruit Street, Boston, MA 02114, USA

* Author to whom correspondence should be addressed; E-Mail: jcusack@mgh.harvard.edu; Tel.: +1-617-724-4093; Fax: +1-617-724-3895.

Received: 28 July 2014; in revised form: 15 September 2014 / Accepted: 24 September 2014 / Published: 17 October 2014

Abstract: Merkel cell carcinoma (MCC) is an aggressive cutaneous neuroendocrine malignancy that is associated with a poor prognosis. The pathogenesis of MCC is not well understood, and despite a recent plethora of mutational analyses, we have yet to find a set of signature mutations implicated in the majority of cases. Mutations, including TP53, Retinoblastoma and PIK3CA, have been documented in subsets of patients. Other mechanisms are also likely at play, including infection with the Merkel cell polyomavirus in a subset of patients, dysregulated immune surveillance, epigenetic alterations, aberrant protein expression, posttranslational modifications and microRNAs. In this review, we summarize what is known about MCC genetic mutations and chromosomal abnormalities, and their clinical significance. We also examine aberrant protein function and microRNA expression, and discuss the therapeutic and prognostic implications of these findings. Multiple clinical trials designed to selectively target overexpressed oncogenes in MCC are currently underway, though most are still in early phases. As we accumulate more molecular data on MCC, we will be better able to understand its pathogenic mechanisms, develop libraries of targeted therapies, and define molecular prognostic signatures to enhance our clinicopathologic knowledge.

Keywords: merkel cell carcinoma; merkel cell polyomavirus; tumor suppressor; oncogene; prognostic algorithm; mutational analysis
1. Introduction

Merkel Cell Carcinoma (MCC) is a rare and aggressive cutaneous neuroendocrine tumor. MCC is most often found in elderly Caucasians approximately 60–80 years old, with an annual incidence in the United States of approximately three cases per million persons per year, though this number has nearly tripled in the last 20 years with an aging populace, increased UV exposure and greater frequency of immunosuppression in the population [1]. MCC can be up to 13 times more frequent in immunosuppressed patient populations including those with HIV, organ transplants and certain hematologic cancers including multiple myeloma, non-Hodgkin’s lymphoma and chronic lymphocytic leukemia [2,3]. Although the relationship between immunosuppression and MCC is not entirely understood, the discovery of the Merkel cell polyomavirus (MCPyV) infection in up to 80% of cases offers a potential mechanism for malignant transformation, and may provide more insight in this regard [4]. The mechanisms of oncogenesis underlying MCPyV-negative MCC are less well understood, but are thought to involve somatic mutations in tumor suppressors including RB1 and TP53, as well epigenetic alterations resulting in aberrant expression and activity of oncogenes [5,6]. The extent of disease at presentation is a strong predictor of survival, ranging from a 70% 10-year-survival rate in patients with isolated local disease, to 20% or less in patients with distant spread [7]. Male sex, tumor size, clinical nodal status, metastatic dissemination, lymphovascular invasion, high mitotic index and small cell morphology are associated with poor prognosis [8,9].

MCC is most frequently found on the head and neck, followed by the upper extremities, lower extremities and trunk. Less than one percent of cases are diagnosed in the parotid and submandibular glands, nasal cavity, and lymph nodes. Tumors present as firm, flesh-colored (often with red or blue hues), painless nodules that are fast growing and tend to metastasize early to lymph nodes and other distant organs. Histopathologically, hematoxylin and eosin staining of MCC presents as round blue tumor cells, indicative of large basophilic nuclei with minimal cytoplasm, located in the dermis or subcutaneous tissue. They may have a trabecular pattern, scant eosinophilic cytoplasmic rims, multiple nucleoli and paranuclear staining of cytokeratin-20 (CK-20) in a dot-like pattern. Normal merkel cells are located within the stratum basale and rete ridges of epidermis, as well as in mucosa [10,11]. They are of ectodermal origin and function in light touch with slow adapting somatosensory afferent fibers. There has been limited debate that MCC may not be derived from merkel cells, but rather pluripotent stems cells within the skin [12].

MCC has historically been difficult to study and treat due to limited epidemiologic data, variable response to treatment and outcomes, and lack of associated genetic mutations for targeted therapy. Approximately half of the available articles on MCC have been published within the last five years, of which few are prospective randomized clinical trials. Although consensus guidelines for management of MCC exist, there are still unanswered fundamental clinical questions regarding the best use of surgery, chemotherapy and radiation for this condition.

2. The Role of Mutational Analysis in MCC

MCC response to treatment modalities and prognosis is variable, and clinical and histologic characteristics have limited utility to predict outcome. Underlying the perplexing natural history of
MCC are unique differences in chromosomal abnormalities, genetic mutations, expression profiles and epigenetic controls of individual tumors that are still poorly understood. Recently, Merkel cell polyomavirus (MCPyV) has been found in up to 80% of MCCs in most reported series and is associated with improved outcome compared to virus negative tumors [13]. Better understanding of MCC at the molecular level will provide much needed insight regarding prognosis, prediction of response to aggressive surgical excision and chemoradiation, and the development of targeted therapy.

3. Merkel Cell Polyomavirus

A key distinction in the mutational analysis of MCC is MCPyV status. Discovered in 2008, this is one of the 13 known polyomaviruses that naturally infect humans, though it is the only human polyomavirus thought to be involved in tumorigenesis [13]. Up to 60%–80% of the normal population will test positive for MCPyV infection, whereas the incidence of infection among MCC patients is approximately 80%–90% [14]. Among those infected, anti-VP1 antigen titer is significantly higher in MCC patients compared to the normal population [15]. It is not understood why the infection rate or antigen titer are higher in MCC patients, or what determines oncogenic transformation in infected patients, though immunocompromise likely plays a role. The incidence of MCC is 15-fold higher among immunocompromised patients, and up to 30-fold higher in patients with certain liquid malignancies [16,17]. However, it has not been validated to our knowledge that the incidence of MCPyV positive MCC is higher in the immunocompromised population than in non-immunocompromised patients. MCPyV status of tumors is independent of patient age, whereas MCPyV status among the normal population is age dependent [18].

The MCPyV virus integrates its DNA into tumor cells in a clonal pattern, preceding tumor proliferation. There are two relevant viral proteins: large T antigen (LT-Ag) and small T antigen (ST-Ag), which have been implicated in oncogenesis through multiple mechanisms. ST-Ag contains an N-terminal J domain similar to LT-Ag, but is otherwise structurally unique. ST-Ag was shown to inhibit proteasomal degradation of LT-Ag and other SCF(bw37) ubiquitin ligase targets, including c-Myc and cyclin E, contributing to oncogenesis [19]. ST-Ag has also been found to transform rodent fibroblasts via preservation of hyperphosphorylation of 4E-BP1 at S65 resulting in dysregulated cap-dependent translation that was resistant to mTORC1 and two inhibitors [20]. 4E-BP1 functions via inhibition of eukaryotic translation initiation factor 4E (eIF4E), which is a limiting component of the multisubunit complex that recruits 40S ribosomal subunits to the 5' end of mRNAs for translation initiation. Knockdown of ST-Ag alone results in growth arrest of MCC cell lines [21].

LT-Ag has four putative regions: an N-terminal J-domain, RB1 and DNA binding motifs, and a C-terminal helicase domain. The viral genomes recovered from MCC tissue contain mutations affecting the helicase and DNA binding regions that selectively inhibit LT-Ag ability to support viral replication, thereby preventing lytic viral replication that could be lethal to a cancer cell, while still maintaining its Rb-binding capacity and cell cycle dysregulating function. The helicase region has been shown to promote growth inhibitory functions, likely through induction of DNA damage response kinases, which may partly explain why signature truncation of this region is found in MCC [22]. Perhaps, the most frequently documented oncogenic function of LT-Ag is its RB1 binding capacity. MCC-derived truncated LT-Ag binds RB1 with high affinity, partially relocalizing the protein to the
cytoplasm and suppressing its anti-neoplastic function [23]. This Rb-sequestering function was shown to be essential to virus positive MCC proliferation both in in vitro and xenograft models [24]. LT-Ag also downregulates expression of TLR9, a key receptor in the host innate immune response that senses viral or bacterial dsDNA, thereby liberating infected cells from host immune surveillance. LT-Ag achieves this effect via inhibition of C/EBPβ binding at the TLR9 promoter [25]. Unlike other polyomaviruses, full length and truncated MCPyV lack TP53-binding capacity [26]. Most MCCs are TP53 wild type and increased TP53 expression is associated with worse prognosis, therefore large and small T antigens may affect TP53 function indirectly.

MCPyV positive tumors are more commonly found in females and are associated with lower stage and better prognosis, including longer overall and disease free survival [4,27–29]. Histologically, MCPyV positive tumors have been found to have less nuclear polymorphism and cytoplasmic content, consistent with their less sinister course. A higher viral copy number per tumor cell is associated with improved survival in complete remission [4]. The association between viral infection and prognosis is poorly understood, though may in part be related to immune response. The presence of tumor infiltrating cytotoxic T cells (CD8+) is independently associated with improved prognosis, and MCPyV positive tumors have greater numbers of intra- and peritumoral CD3+ and CD8+ T cells [30,31].

Targeted immunotherapy towards T cell antigens and their downstream targets may be promising for virus positive tumors. Although up to 80% of the general population will harbor antibodies to MCPyV capsid proteins, titers are significantly higher in MCC patients, who also uniquely generate antibodies to T antigens. Anti-T antigen titer may be used as a biomarker for disease regression or recurrence in a subset of patients. Monoclonal antibodies, vaccines and adoptive cellular approaches targeting T antigens and other MCC-specific tumor antigens are being studied as potential therapeutic modalities [33].

4. Mutations in Tyrosine Kinase Signaling: KIT, PDGFRA, PIK3CA, AKT and PTEN

PDGFRA and KIT (CD117) are transmembrane receptor tyrosine kinases associated with certain cancers including melanoma and acute myeloid leukemia, and activating mutations in both genes have been associated with tumorigenesis [34]. MCCs have been found to express both proteins, warranting investigation as therapeutic targets [35].

Andea et al. evaluated KIT expression in 30 MCC tumors, which was elevated in 67% of cases and was associated with a trend towards worse prognosis. Point mutations were found in exons 17 and 18, and introns 16 and 17, though no activating mutations were identified [36]. In a similar study, 23 cases of MCC were evaluated for KIT and PDGFRA expression and mutational status. 65% of tumors expressed CD117 and 95% expressed PDGFRA. In 12 of 18 samples, a single nucleotide polymorphism (SNP) in KIT exon 11 resulted in an E583K amino acid change, which has previously been described as an inactivating mutation in piebaldism, and is unlikely related to tumorigenesis. A SNP with silent effect in exon 18 of PDGFRA was found in eight of 18 samples [37]. Kartha et al.
evaluated 14 primary and 18 metastatic MCC tumors for KIT and PDGFRα expression and mutation. KIT and co-expression of its ligand, SCF, was found in 16% of cases, whereas co-expression of PDGFA and PDGFRα was observed in 81% of cases. Silent mutations were observed in exon 17 of KIT and exons 10, 12 and 18 of PDGFRα, but activating mutations were not found [38]. Based on these findings, activating mutations in KIT and PDGFRα receptor tyrosine kinases are unlikely drivers of MCC tumorigenesis. Although these proteins may play a role in MCC cellular proliferation and survival, the mechanism underlying their aberrant expression and activity is poorly understood.

Nardi et al. sequenced select mutational hotspots of 60 MCC tumors and found three (5%) TP53 point mutations and six (10%) PIK3CA activating point mutations [39]. PIK3CA has been implicated in multiple cancers including: liver (36%), breast (26%), colon (25%), urothelial (13%), ovarian (9%), gastric (7%), brain (6%), and lung cancer (2%) as well as leukaemia (1%) [40,41]. It serves as an intracellular tyrosine kinase that activates AKT downstream to stimulate cell cycle progression via mTOR, cellular proliferation via NF-κb, and inhibition of apoptosis via deactivation of tumor suppressors including TP53, p21, p27 and GSK3b. Five of the six PIK3CA mutations observed were within the helical domain of the p110α subunit, which is mutated in a wide variety of skin cancers [42]. These mutations were exclusively found in men, and associated tumors included a mix of primary and recurrent disease, had a normal distribution pattern, were significantly larger in size (>2 cm) with worse stage, had more necrosis and pleomorphic spindle cell features, and all were MCPyV negative except for one case. However, the authors were unable to correlate these findings to worse prognosis, likely due to limited power. They tested multiple PIK3CA inhibitors and were able to inhibit phosphorylation and activation of AKT in multiple MCC cell lines and induce apoptosis in one line with both ZST474, a specific phosphoinositide 3-kinase (PI3K) inhibitor, and NVP-BEZ235, a dual PI3K/mTOR inhibitor. Although no mutations were observed in the AKT gene, it was shown that a subset of MCC samples display high AKT activity in the setting of wild type PIK3CA, suggesting upstream activation either through an unknown oncogene or disinhibition from mutated tumor suppressor, specifically PTEN [39].

Hafner et al. also evaluated the PIK3CA pathway in MCC and found 2/46 (4%) MCC had PIK3CA mutations and none in AKT. However, activating phosphorylation of AKT was found in 88% of MCCs, which was uncorrelated with MCPyV status, and cells were sensitive to the PIK3CA inhibitor LY-294002 [43]. Based on these data, upstream or epigenetic aberrations are likely driving the pathway given the lack of intrinsic mutations.

PTEN (phosphatase and tensin homologue) is a tumor suppressor implicated in many cancer types, which functions by inactivating AKT via dephosphorylation. Chromosomal analysis of 21 MCC samples showed hemizygous mutations in nine (43%) samples of the10q23 region of Ch10, where PTEN is located. However, homozygous deletions or point mutations of the remaining allele were quite rare, suggesting alternate mechanisms of PTEN inactivation or the involvement of other tumor suppressors in MCC [44].

More work is needed to elucidate the mechanisms of constitutive PIK3CA/AKT activation in MCC given the relative paucity of pathway mutations, and to better characterize the function of these genetic aberrations in oncogenesis and prognosis. Tyrosine kinase inhibitors may still play an important chemotherapeutic role, and there are currently multiple ongoing clinical trials (Table 1). Most are still
in early phases and incomplete. The only completed to date trial is a phase II study of imatinib that showed no benefit in advanced MCC patients [45].

Table 1. Clinical trials for tyrosine kinase inhibitors in Merkel Cell Carcinoma (MCC).

| Generic Name | Trade/Code Name | Mechanism of Action | Trials in other Cancers | MCC | Trial Status | Additional |
|--------------|-----------------|---------------------|-------------------------|-----|--------------|------------|
| Pazopanib    | Votrient        | Multi-targeted tyrosine kinase inhibitor | Renal cell, soft tissue sarcoma, lung, ovarian, breast, prostate, neuroendocrine, thyroid, cervical, cholangiocarcinoma, germ cell, urothelial and fallopian tube cancers | Phase 2 | Recruiting | In combination with Everolimus |
| Cabozantinib | Cometriq        | Targeted inhibitor of c-Met and VEGFR2 | Thyroid, melanoma, breast, pancreatic, prostate, brain, bladder and ovarian cancers Pancreatic, brain, cervical, head and neck, rectal, soft tissue sarcoma, and non-small cell lung cancers | Phase 2 | Recruiting | Separate trials in combination with Cixutumumab and Vatalanib |
| Nelfinavir   | Viracept        | Monoclonal antibody targeting IGF-1R | Esophageal, soft tissue sarcoma, lung, liver, prostate, melanoma, breast, colorectal and thymoma cancers | Phase 1 | Unknown | In combination with Everolimus |
| Cixutumumab  | IMC-A12         | Inhibitor of mTOR | Breast, brain, pancreatic, liver, colorectal, lung, head and neck, fallopian tube, gastric, thyroid, prostate, endometrial, renal cell, and cervical cancers | Phase 1 | Ongoing, not recruiting ** | Separate trials in combination with Everolimus |
| Everolimus   | Afinitor        | Inhibitor of mTOR | Hematologic, GIST, pancreatic, brain, colorectal, prostate, breast, melanoma, lung and mesothelioma cancers Thyroid, prostate, breast, liver, head and neck, endometrial, ovarian, neuroendocrine, gastric, cervical, pancreatic, renal, lung, colorectal, esophageal and brain cancers | Phase 1 | Ongoing, not recruiting | In combination with Everolimus |
| Vatalanib    | PTK787          | Inhibitor of VEGF-1 and 2, PDGFRβ and KIT | Hematologic, GIST, pancreatic, brain, colorectal, prostate, breast, melanoma, lung and mesothelioma cancers Thyroid, prostate, breast, liver, head and neck, endometrial, ovarian, neuroendocrine, gastric, cervical, pancreatic, renal, lung, colorectal, esophageal and brain cancers | Phase 1 | Ongoing, not recruiting | In combination with Vinorelbine |
| Temsirolimus | Torisel         | Inhibitor of mTOR | Hematologic, GIST, ovarian, breast, and head and neck, lung, colorectal, thyroid, testicular, prostate, renal, gastric, brain, melanoma, pancreatic and sarcoma cancers | Phase 1 | Ongoing, not recruiting | |
| Imatinib     | Gleevec         | Inhibitor of BCR-ABL | | Phase 2 | Completed | No observed benefit |

VEGFR2, Vascular Endothelial Growth Factor Receptor 2; IGF-1R, Insulin Growth Factor-1 Receptor; mTOR, Mammalian Target of Rapamycin; VEGF-1/2, Vascular Endothelial Growth Factor 1/2; PDGFRβ, Platelet Derived Growth Factor Receptor Beta; BCR-ABL, Breakpoint Cluster Region-Abelson Murine Leukemia gene. * Everolimus and Cixutumumab combination therapy trial; ** Everolimus and Vatalanib combination therapy trial.
5. Mutations in Tumor Suppressors: TP53 and RB1

Mutations in the TP53 tumor suppressor have rarely been found in MCC, ranging from 0%–28% in most studies, the majority of which represent SNPs or silent mutations with unknown or no clinical significance [53–56]. Of note, Waltari et al. 2011 analyzed 87 MCC tumors and found no TP53 mutations, though TP53 protein expression was detected in 22.8% of samples, and was associated with MCPyV negative status and worse disease specific \( (p = 0.021) \) and overall survival \( (p = 0.46) \) [55]. Lassacher et al. evaluated 21 MCC tumors for mutations in tumor suppressors and oncogenes commonly seen in skin cancers. They found three mutations in TP53 (14%) and one mutation in p16INK4a, though no mutations in Ha-Ras, N-Ras, KIT or p14ARF. However, inactivating p14ARF promoter methylation was present in eight of 19 analyzable samples (42%), suggesting that epigenetic tumor suppressor silencing may play a role in MCC oncogenesis [56]. In contrast, the tumor suppressor p73, a structural homologue of TP53, was mutated in four of 15 MCC samples, with unclear significance [57]. Based on these studies, TP53 inactivating mutations unlikely contribute to MCC oncogenesis.

Prior work has validated that TP53 expression is a marker for poor prognosis in multiple tumor types [58]. Normal functioning TP53 is typically undetectable at the protein level due to its short half-life and rapid turnover. Although in certain cases missense mutations in TP53 can prevent its degradation and tumor suppressive function, the majority of MCC samples studied to date have had wild type TP53, and therefore other mechanisms are likely at play. In this regard, the mouse double minute 2 homolog (MDM2) protein may be of therapeutic significance. This protein forms a complex with TP53 in the cytoplasm, preventing the tumor suppressor from binding its responsive element and initiating anti-proliferative and DNA repair mechanisms. Due to this sequestration, TP53 accumulates and remains nonfunctional [59]. This process has been described in sarcoma, where it was shown that MDM2 was amplified in one third of 47 samples, and was specifically associated with detectable expression of TP53 [60]. Houben et al. looking specifically at MCC, studied whether T antigens contributed to TP53 stabilization and found that viral knockdown did not lead to resumed TP53 function. However, they found that inhibition of MDM2 by the compound Nutlin-3a did induce TP53 transcriptional activation, resulting in tumor cell apoptosis in five of seven lines with wild type TP53 [61].

Retinoblastoma (Rb) inactivation is thought to play an important role in the pathogenesis of MCC. In MCPyV-positive cancers, sustained tumor growth is contingent on the presence of a functional large T antigen with intact RB1 binding domain to sequester and inactivate the tumor suppressor, which may serve as an important therapeutic target for the subset of MCPyV-positive cancers [23,24]. RB1 is also frequently downregulated in virus negative tumors, though the mechanisms of inactivation are still under investigation. Leonard et al. evaluated 24 MCC samples for hemizygous deletions, and found that 75% of tumors contained deletions in chromosome 13 near the RB1 locus [62]. A separate study showed that virus negative tumors had increased genomic instability compared to virus positive MCCs with higher rates of deletion in the RB1 locus that correlated with decreased RB1 detection by immunohistochemistry. Additionally, they found RB1 promoter hypermethylation in all tumor samples, irrespective of MCPyV status and RB1 expression [5]. In addition to chromosomal deletion, a higher frequency of nonsense truncating mutations in the RB1 gene has been shown in MCPyV-negative tumors [63].
6. Chromosomal Abnormalities

Chromosomal aberrations can potentially provide insights into the pathogenesis of MCC, reveal specific gene targets, and serve as a diagnostic resource. Initial forays into chromosomal analysis in MCC utilized comparative genomic hybridization (CGH) to define copy number abnormalities, but lacked the resolution to isolate specific gene candidates. Frequently amplified regions have been found on chromosomes 1, 5, 6, 8 and 20, and frequent losses on chromosomes 13 and 4 (Table 2) [6,64,65]. Chromosomal alterations are associated with larger tumors at higher risk for metastatic dissemination [64]. However, most studies lack evidence for high-level amplifications [66]. The advent of microarrays has greatly improved the resolution of hybridization, and can provide copy number information at the single gene level. Using array-CGH technology, Paulson et al. evaluated 23 MCC samples, and similarly found that tumors frequently carried additional copy regions of chromosomes 1, 3q, 5p, and 6 and lost chromosomes 3p, 4, 5q, 7, 10 and 1. MCPyV positive tumors had fewer genetic alterations. Three chromosomal regions were of interest, including a deletion of 5q12–21 found in 26% of tumors, a deletion of 13q14–21 also found in 26% of tumors that contains the RB1 tumor suppressor, and amplification at 1p34 present in 39%, which contains the L-Myc (MYCL1) oncogene [67].

| Chromosome | Deletion/Amplification |
|------------|------------------------|
| 1          | Amplification of 1p34 in 9/23 (39%) tumor samples, contains L-Myc [67]. Deletion of 1p32–33, 1p35 and 1p36 in 16/24 (73%) of MCC tumor samples, 1p36.33 contains p73 tumor suppressor [57]. |
| 3          | Amplification of 1q11q31 in 32% of 19 primary MCC tumors analyzed, high-level amplification of 1q22q24 in 5% of samples [64]. Deletion of 1p35–36 in 7/10 (70%) of MCC samples [68]. Deletion of 1p arm in 3/3 (100%) of MCC samples [69]. |
| 5          | Amplification of 5p in 32% and high-level amplification of 5p in 5% of 19 MCC samples [64]. Deletion of 5q12–21 in 26% cases of 23 tumor samples [67]. |
| 6          | Amplification of 6p in 8/19 cases (42%), most common 6pterqter [64]. Trisomy in 8/17 cases (47%) [72]. Trisomy in 2/4 lymph nodes samples and 6/10 primary tumor samples [73]. Trisomy documented in a single patient case report of disease recurrence [74]. |
| 7          | Case report documented deletion of the long arm with break point at 7q31, as well as trisomy of chromosomes 6 and 11 [75]. |
| 8          | Trisomy documented in a single patient case report of disease recurrence [74]. Amplification of 8q21–q22 and loss of 4p15-pter [6]. |
| 10         | Deletion of 10q23 in 9/21 (43%) cases, containing the PTEN locus [44]. |
| 13         | Deletion of 13q13q31 (21%), 4q (16%), and 16q (11%) in 19 MCC samples [64]. Deletion of 13q14–21 in 26% of 23 tumor samples [67]. Deletion of 13p in 18/24 75% cases, most commonly deleted region was mapped close to the RB1 susceptibility gene 13p14.3 [62]. |
| 22         | Case report documenting deletion of 22p in 100% and 22q in 85% of MCC cells from a patient sample [76]. |

Table 2. Chromosomal abnormalities in MCC.

PTEN, Phosphatase and tensin homolog.
7. MicroRNAs

MicroRNAs (miRNAs) are non-coding RNA sequences approximately 18–22 bases in length that silence translation of complementary messenger RNA transcripts, thereby regulating post-transcriptional gene expression. Discovered within the last 20 years, miRNAs have been shown to play critical roles in multiple biologic processes, and they are often deregulated in cancers. Certain miRNAs have been directly linked to oncogenesis, and provide potential diagnostic, therapeutic and prognostic value.

Xie et al. evaluated miRNA expression patterns of MCC, and found distinct expression profiles based on MCPyV status. Specifically, miR-203, miR-30a-3p, miR-769-5p, miR-34a, miR-30a-5p, and miR-375 were significantly different between the two groups. They also identified multiple miRNAs associated with decreased survival and metastases, including: miR-150, mi-146, miR-630, miR-483-5p, and miR-142-3p. However, only miR-150 was statistically significant, and may potentially serve as a useful prognostic marker [77].

MiR-203 suppresses multiple targets involved in oncogenesis, and is downregulated in certain cancers [78–81]. In MCC, miR-203 has been shown to suppress expression of survivin, a highly conserved member of the inhibitor of apoptosis (IAP) family that is overexpressed and contributes to tumorigenesis [82]. Xie et al. showed that miR-203 overexpression resulted in decreased transcript and protein detection of the survivin gene, which was associated with increased cell cycle arrest, though in MCPyV negative cells only. In virus positive tumors, LT-Ag is thought to inhibit survivin expression via sequestration of the RB1 tumor suppressor, and RNA silencing of LT-Ag was able to restore susceptibility to miR-203 overexpression. Thus, survivin expression appears to be differentially regulated by miR-203 and LT-Ag in virus negative and positive MCCs, respectively [77]. Recently, YM-155, a direct survivin inhibitor, has been shown be cytotoxic to MCPyV positive MCC cells at nanomolar concentrations in mouse xenografts, improving survival, and therefore may serve as a potential therapeutic target for MCC [83]. In MCPyV negative cells, miR-203 delivery may provide an alternative novel therapeutic target.

Ning et al. evaluated the miRNome in MCC and found significant upregulation of miR-502-3p, miR-9, miR-7, miR-340, miR-182, miR-190b, miR-873, and miR-183 relative to non-MCC cutaneous tumors and normal skin controls. They found downregulation of miR-3170, miR-125b, and miR-374c [84]. miR-125b downregulation in breast and hepatocellular carcinomas is associated with disinhibition of cellular proliferation and anti-apoptotic programs, and overexpression may restore regulatory mechanisms [85]. In contrast, in melanoma, miR-182 expression is associated with tumor proliferation and invasion, likely via suppression of the FOXO3 tumor suppressor [86]. The role of under- and overexpression of miRNAs in MCC is still poorly understood, though may provide a novel library of therapeutic targets.

8. Negative Mutational Findings

MCC pathogenesis has been difficult to characterize given the abundance of negative mutational studies (Table 3). To date, several highlights have been reported: mutations in TP53 ranging from approximately 5%–28% in most series, variable deletion of the RB1 locus, and more recently, a novel study reporting a 10% frequency of mutation of PIK3CA in 60 MCC samples [5,39,56]. Aberrant
expression and activity of both tumor suppressors and oncogenes have been frequently documented in MCC, yet the paucity of associated mutations suggests that this cancer may lack a defining profile such as the BCR-ABL mutation in chronic myelogenous leukemia. Rather, oncogenesis is likely predicated on poorly understood dysregulated processes including epigenetic programs, post-transcriptional gene regulation, and post-translational modifications.

Table 3. Mutational analyses with negative findings in MCC.

| Negative Study          | Description                                                                 |
|------------------------|-----------------------------------------------------------------------------|
| p14ARF, p16INK4, H-Ras, K-Ras, N-Ras, KIT | 1/20 (5%) p16INK4 mutations, no mutations in any of the other genes; hypermethylation of p14ARF suggesting downregulation of the tumor suppressor [56]. |
| p73 and TP53           | Missense mutation in p73 of unclear significance in 15 samples. One TP53 nonsense mutation [57]. |
| PTEN                   | Hemizygous mutations in 9/21 MCC samples, though remaining allele unmutated. Epigenetic silencing of remaining allele is possible though yet to be shown [44]. |
| PDGFA                  | Expression detected in 25/31 (81%) of cases, though no activating mutations [38]. |
| c-KIT                  | Expressed in 8/9 (89%) of cases, though no activating mutations [87]. |
| Wnt                    | Elevated β-catenin in only 1/12 (8%) cases, no mutations. Similarly no mutations in APC [88]. Lill et al. 2013 found no increased expression of β-catenin or cyclin D in MCC samples [89]. |
| BRAF                   | No mutations in exon 15 (commonly mutated region in melanoma) in 15 samples tested [90]. No. V600E mutations, which is found in 43% of melanomas, in 46 MCC samples [91]. |
| MAPK Pathway           | High expression of Raf Kinase Inhibitor Protein (RKIP), which deactivates the pathway. Expression though lack of phosphorylated activation of ERK in 42/44 (95%) cases, representing lack of activation [91]. |
| ALK                    | Expressed in 26/32 (81%) of MCC samples, no rearrangement or other cytogenetic abnormality of the locus identified [92]. |
| HRAS, KRAS, NRAS, BRAF, cKIT | No mutations in exons 1 and 2 of all genes studied in 6 MCC cell lines [6]. |
| RON and MSP            | No mutations, though transcription of both genes in 9/14 MCC samples and no controls [93]. |
| Notch-1                | Tumor suppressor downregulated in lung and gastrointestinal neuroendocrine tumors, found to be expressed in 30/31 (97%) of MCC samples, thus unlikely to play a role in oncogenesis. Mutational status no evaluated [94]. |
| APC, BRAF, β-catenin, EGFR, FLT3, JAK2, cKIT, KRas, NRas, Notch-1, PTEN | No mutations in hotspots of these genes in 60 MCC samples [39]. |

p14ARF, p14 Alternate Reading Frame; Ras, Rat Sarcoma; PTEN, Phosphatase and tensin homolog; PDGFA, Platelet Derived Growth Factor Alpha; Wnt, Wingless-related integration site; BRAF, Rapidly Accelerated Sarcoma B; MAPK, Mitogen Activated Protein Kinase; ALK, Anaplastic Lymphoma Kinase; RON, Recepteur d’Origine Nantais; MSP, Macrophage Stimulating Protein; APC, Adenomatous Polyposis Coli; EGFR, Epidermal Growth Factor Receptor; FLT3, FMS-like Tyrosine Kinase 3; JAK2, Janus Kinase 2.
9. Molecular Prognostic Algorithm

Although MCC prognosis is on average quite poor, there is considerable range in survival, yet we have limited capacity to predict outcome. Most studies on survival in MCC have historically focused on clinicopathologic features including tumor size and location, histologic features such as nuclear atypia and lymphovascular invasion, and metastases to lymph nodes and distant sites. However, with advances in molecular diagnostics, characterization of MCC signatures will provide better accuracy for predicting prognosis in the individual patient. There are already multiple studies correlating expression of one or several genes with prognosis in MCC, typically via protein expression using immunohistochemistry (IHC), and the information from these resources could be synthesized to create a prognostic molecular profile (Table 4). MCPyV status may also be an important bifurcation, as virus negative tumors have been shown to have worse prognosis in some series (Figure 1) [32,39].

**Table 4.** Markers associated with prognosis in MCC.

| Expressed Marker               | Association with MCC Prognosis                                                                                                                                 |
|--------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------|
| MCPyV                          | Associated with LT-Ag and RB1 expression and absence of TP53 expression, and was associated with improved disease specific and overall survival (p < 0.01) on univariate analysis [95]. Polymavirus-positive Merkel cell carcinomas showed better prognosis with one spontaneous regression case and significantly higher expression of retinoblastoma protein (p = 0.0003) and less TP53 expression (p = 0.0005) compared to MCPyV negative MCC [32]. |
| Intratumoral CD8               | Independent predictor of survival on multivariate analysis (p = 0.01) [31].                                                                                                                                              |
| Anti-LTAg                      | Associated with MCPyV infection, titer level correlated with disease progression. Rise in T-Ag titer preceded tumor recurrence, may have biomarker potential [96].                                                             |
| Anti-VP1                       | High anti-VP1 titers associated with improved progression free survival in MCC patients (p = 0.003) [97].                                                                                                                |
| p63                            | p63 is expressed in more advanced disease, though its role as a prognostic tool is undetermined. In two different series, p63 expression was significantly associated with decreased survival [98,99]. However, a separate study of 95 patients found no correlation between p63 and prognosis [100]. |
| Ki-67                          | Ki-67 labeling index exceeding 50% correlated with poor prognosis [101].                                                                                                                                                 |
| Ep-CAM                         | Highly expressed in metastasizing MCC [102].                                                                                                                                                                             |
| Cyclin A, Tenasin-C             | Associated with worse prognosis [103].                                                                                                                                                                                   |
| Patched and IHH                | Sonic Hedgehog (SHH) pathway proteins were frequently and intensely over-expressed in the MCCs in this study (Sonic hedgehog, 93%; Indian hedgehog, 84%; Patched, 86%; Smoothened, 79%; Gli-1, 79%; Gli-2, 79%; Gli-3, 86%) compared with control samples. High levels of Patched and Indian hedgehog were significantly associated with an increase in patients overall (p = 0.015) and recurrence-free survival (p = 0.011), respectively [104]. |
| MMP2/7/10, TIMP3, VEGF, P38,   | Expression correlated with metastatic tumor spread [105].                                                                                                                                                                |
| NF-kappaB, and Synaptophysin    | Binds and stabilizes TP53, causing cell cycle arrest and growth inhibition. Found to be expressed in all 27 MCC samples studied to varying degrees. High expression was significantly associated with improved overall survival (50% 5-years survival vs. 14%; p = 0.03) [106]. |
| PIN1                           | miR-150, mi-146, miR-630, miR-483-5p, and miR-142-3p associated with worse prognosis, though only miR-150 reached statistical significance [77].                                                                           |
| miR-150                        |                                                                                                                                                                                                                         |
| CD34 and Chromogranin          | Trend towards favorable prognosis [107].                                                                                                                                                                                 |

MCPyV, Merkel cell; Rb, Retinoblastoma; Ep-CAM, Epithelial Cell Adhesion Molecule; IHH, Indian Hedgehog; MMP, matrix metalloproteinase; TIMP3, Tissue Inhibitor of Metalloproteinase 3; VEGF, Vascular Endothelial Growth Factor; PIN1, Peptidyl-prolyl cis-trans isomerase 1.
10. Conclusions

Despite a recent plethora of mutational studies in MCC, we have yet to find a disruptive pathway that is the driving factor in the majority of cases. Mutations in TP53, Rb, and PIK3CA, found in the minority of patients, may provide an avenue for the development of therapeutic targets for certain patients. However, as this review suggests, continued searches for gene mutations, which are only one facet of cancer pathophysiology, may be of limited value. Many of the oncologic pathways seen in other cancers have been rigorously evaluated for missense and nonsense mutations in MCC with disappointingly low yield. It is possible that we have merely been looking at the wrong pathways, and defining mutations are waiting to be discovered. However, as many of these studies have serendipitously found, although certain oncogenes are not mutated, they have abnormally high expression and activity that is likely still of clinical significance. MCC is elusive in that perhaps many
of the driving mechanisms of this cancer are imbedded in still poorly understood processes such as immune surveillance, epigenetic alterations, aberrant protein expression, posttranslational modifications and microRNAs. Going forward, application of functional genomics and proteomics is greatly needed to provide the insights necessary to develop effective therapies.

Acknowledgements

The authors would like to thank all members of the Massachusetts General Hospital Cancer Center for the useful conversations and support.

Author Contributions

D.E. wrote the body of the text, created the tables and figure. J.C. provided expert opinion and content overview.

Conflicts of Interest

The authors declare no conflict of interest.

References

1. Agelli, M.; Clegg, L.X.; Becker, J.C.; Rollison, D.E. The etiology and epidemiology of merkel cell carcinoma. *Curr. Probl. Cancer* 2010, 34, 14–37.
2. Lunder, E.J.; Stern, R.S. Merkel-cell carcinomas in patients treated with methoxsalen and ultraviolet a radiation. *N. Engl. J. Med.* 1998, 339, 1247–1248.
3. Howard, R.A.; Dores, G.M.; Curtis, R.E.; Anderson, W.F.; Travis, L.B. Merkel cell carcinoma and multiple primary cancers. *Cancer Epidemiol. Biomarkers Prev.* 2006, 15, 1545–1549.
4. Laude, H.C.; Jonchere, B.; Maubec, E.; Carlotti, A.; Marinho, E.; Couturaud, B.; Peter, M.; Sastre-Garau, X.; Avril, M.F.; Dupin, N.; et al. Distinct merkel cell polyomavirus molecular features in tumour and non tumour specimens from patients with merkel cell carcinoma. *PLoS Pathog.* 2010, 6, e1001076.
5. Sahi, H.; Savola, S.; Sihto, H.; Koljonen, V.; Bohling, T.; Knuutila, S. Rb1 gene in merkel cell carcinoma: Hypermethylation in all tumors and concurrent heterozygous deletions in the polyomavirus-negative subgroup. *APMIS* 2014, doi:10.1111/apm.12274.
6. Popp, S.; Waltering, S.; Herbst, C.; Moll, I.; Boukamp, P. Uv-b-type mutations and chromosomal imbalances indicate common pathways for the development of merkel and skin squamous cell carcinomas. *Int. J. Cancer* 2002, 99, 352–360.
7. Albores-Saavedra, J.; Batich, K.; Chable-Montero, F.; Sagy, N.; Schwartz, A.M.; Henson, D.E. Merkel cell carcinoma demographics, morphology, and survival based on 3870 cases: A population based study. *J. Cutan. Pathol.* 2010, 37, 20–27.
8. Andea, A.A.; Coit, D.G.; Amin, B.; Busam, K.J. Merkel cell carcinoma: Histologic features and prognosis. *Cancer* 2008, 113, 2549–2558.
9. Skelton, H.G.; Smith, K.J.; Hitchcock, C.L.; McCarthy, W.F.; Lupton, G.P.; Graham, J.H. Merkel cell carcinoma: Analysis of clinical, histologic, and immunohistologic features of 132 cases with relation to survival. *J. Am. Acad. Dermatol.* 1997, 37, 734–739.

10. Wong, H.H.; Wang, J. Merkel cell carcinoma. *Arch. Pathol. Lab. Med.* 2010, 134, 1711–1716.

11. Hanly, A.J.; Elgart, G.W.; Jorda, M.; Smith, J.; Nadji, M. Analysis of thyroid transcription factor-1 and cytokeratin 20 separates merkel cell carcinoma from small cell carcinoma of lung. *J. Cutan. Pathol.* 2000, 27, 118–120.

12. Tilling, T.; Moll, I. Which are the cells of origin in merkel cell carcinoma? *J. Skin Cancer* 2012, doi:10.1155/2012/680410.

13. Feng, H.; Shuda, M.; Chang, Y.; Moore, P.S. Clonal integration of a polyomavirus in human merkel cell carcinoma. *Science* 2008, 319, 1096–1100.

14. Coursaget, P.; Samimi, M.; Nicol, J.T.; Gardair, C.; Touze, A. Human merkel cell polyomavirus: Virological background and clinical implications. *APMIS* 2013, 121, 755–769.

15. Pastrana, D.V.; Tolstov, Y.L.; Becker, J.C.; Moore, P.S.; Chang, Y.; Buck, C.B. Quantitation of human seroresponsiveness to merkel cell polyomavirus. *PLoS Pathog.* 2009, 5, e1000578.

16. Heath, M.; Jaimes, N.; Lemos, B.; Mostaghimi, A.; Wang, L.C.; Penas, P.F.; Nghiem, P. Clinical characteristics of merkel cell carcinoma at diagnosis in 195 patients: The aeiou features. *J. Am. Acad. Dermatol.* 2008, 58, 375–381.

17. Tadmor, T.; Aviv, A.; Polliack, A. Merkel cell carcinoma, chronic lymphocytic leukemia and other lymphoproliferative disorders: An old bond with possible new viral ties. *Ann. Oncol.* 2011, 22, 250–256.

18. Harms, P.W.; Patel, R.M.; Verhaegen, M.E.; Giordano, T.J.; Nash, K.T.; Johnson, C.N.; Daignault, S.; Thomas, D.G.; Gudjonsson, J.E.; Elder, J.T.; et al. Distinct gene expression profiles of viral- and nonviral-associated merkel cell carcinoma revealed by transcriptome analysis. *J. Investig. Dermatol.* 2013, 133, 936–945.

19. Kwun, H.J.; Shuda, M.; Feng, H.; Camacho, C.J.; Moore, P.S.; Chang, Y. Merkel cell polyomavirus small T antigen controls viral replication and oncoprotein expression by targeting the cellular ubiquitin ligase SCFFbw7. *Cell Host Microbe* 2013, 14, 125–135.

20. Shuda, M.; Kwun, H.J.; Feng, H.; Chang, Y.; Moore, P.S. Human merkel cell polyomavirus small T antigen is an oncoprotein targeting the 4e-bpf1 translation regulator. *J. Clin. Investig.* 2011, 121, 3623–3634.

21. Shuda, M.; Chang, Y.; Moore, P.S. Merkel cell polyomavirus-positive merkel cell carcinoma requires viral small T-antigen for cell proliferation. *J. Investig. Dermatol.* 2014, 134, 1479–1481.

22. Li, J.; Wang, X.; Diaz, J.; Tsang, S.H.; Buck, C.B.; You, J. Merkel cell polyomavirus large T antigen disrupts host genomic integrity and inhibits cellular proliferation. *J. Virol.* 2013, 87, 9173–9188.

23. Borchert, S.; Czech-Sioli, M.; Neumann, F.; Schmidt, C.; Wimmer, P.; Dobner, T.; Grundhoff, A.; Fischer, N. High-affinity Rb binding, p53 inhibition, subcellular localization, and transformation by wild-type or tumor-derived shortened merkel cell polyomavirus large T antigens. *J. Virol.* 2014, 88, 3144–3160.
Cancers 2014, 6

24. Houben, R.; Adam, C.; Baeurle, A.; Hesbacher, S.; Grimm, J.; Angermeyer, S.; Henzel, K.; Hauser, S.; Elling, R.; Brocker, E.B.; et al. An intact retinoblastoma protein-binding site in merkel cell polyomavirus large T antigen is required for promoting growth of merkel cell carcinoma cells. *Int. J. Cancer* 2012, 130, 847–856.

25. Shahzad, N.; Shuda, M.; Gheit, T.; Kwun, H.J.; Cornet, I.; Saidj, D.; Zannetti, C.; Hasan, U.; Chang, Y.; Moore, P.S.; et al. The T antigen locus of merkel cell polyomavirus downregulates human toll-like receptor 9 expression. *J. Virol.* 2013, 87, 13009–13019.

26. Cheng, J.; Rozenblatt-Rosen, O.; Paulson, K.G.; Nghiem, P.; DeCaprio, J.A. Merkel cell polyomavirus large T antigen has growth-promoting and inhibitory activities. *J. Virol.* 2013, 87, 6118–6126.

27. Santamaria-Barria, J.A.; Boland, G.M.; Yeap, B.Y.; Nardi, V.; Dias-Santagata, D.; Cusack, J.C., Jr. Merkel cell carcinoma: 30-year experience from a single institution. *Ann. Surg. Oncol.* 2013, 20, 1365–1373.

28. Sihto, H.; Kukko, H.; Koljonen, V.; Sankila, R.; Bohling, T.; Joensuu, H. Clinical factors associated with merkel cell polyomavirus infection in merkel cell carcinoma. *J. Natl. Cancer Inst.* 2009, 101, 938–945.

29. Bhatia, K.; Goedert, J.J.; Modali, R.; Preiss, L.; Ayers, L.W. Immunological detection of viral large T antigen identifies a subset of merkel cell carcinoma tumors with higher viral abundance and better clinical outcome. *Int. J. Cancer* 2010, 127, 1493–1496.

30. Iyer, J.G.; Afanasiev, O.K.; McClurkan, C.; Paulson, K.; Nagase, K.; Jing, L.; Marshak, J.O.; Dong, L.; Carter, J.; Lai, I.; et al. Merkel cell polyomavirus-specific cd8(+) and cd4(+) T-cell responses identified in merkel cell carcinomas and blood. *Clin. Cancer Res.* 2011, 17, 6671–6680.

31. Paulson, K.G.; Iyer, J.G.; Tegeder, A.R.; Thibodeau, R.; Schelter, J.; Koba, S.; Schrama, D.; Simonson, W.T.; Lemos, B.D.; Byrd, D.R.; et al. Transcriptome-wide studies of merkel cell carcinoma and validation of intratumoral cd8+ lymphocyte invasion as an independent predictor of survival. *J. Clin. Oncol.* 2011, 29, 1539–1546.

32. Higaki-Mori, H.; Kuwamoto, S.; Iwasaki, T.; Kato, M.; Murakami, I.; Nagata, K.; Sano, H.; Horie, Y.; Yoshida, Y.; Yamamoto, O.; et al. Association of merkel cell polyomavirus infection with clinicopathological differences in merkel cell carcinoma. *Hum. Pathol.* 2012, 43, 2282–2291.

33. Triozzi, P.L.; Fernandez, A.P. The role of the immune response in merkel cell carcinoma. *Cancers* 2013, 5, 234–254.

34. Chompret, A.; Kannengiesser, C.; Barrois, M.; Terrier, P.; Dahan, P.; Tursz, T.; Lenoir, G.M.; Bressac-De Paillerets, B. PDGFRA germline mutation in a family with multiple cases of gastrointestinal stromal tumor. *Gastroenterology* 2004, 126, 318–321.

35. Swick, B.L.; Ravdel, L.; Fitzpatrick, J.E.; Robinson, W.A. Platelet-derived growth factor receptor alpha mutational status and immunohistochemical expression in merkel cell carcinoma: Implications for treatment with imatinib mesylate. *J. Cutan. Pathol.* 2008, 35, 197–202.

36. Andea, A.A.; Patel, R.; Ponnazhagan, S.; Kumar, S.; DeVilliers, P.; Jhala, D.; Eltoum, I.E.; Siegal, G.P. Merkel cell carcinoma: Correlation of kit expression with survival and evaluation of kit gene mutational status. *Hum. Pathol.* 2010, 41, 1405–1412.
37. Swick, B.L.; Srikantha, R.; Messingham, K.N. Specific analysis of KIT and PDGFR-alpha expression and mutational status in merkel cell carcinoma. J. Cutan. Pathol. 2013, 40, 623–630.
38. Kartha, R.V.; Sundram, U.N. Silent mutations in kit and pdgfra and coexpression of receptors with SCF and PDGFA in merkel cell carcinoma: Implications for tyrosine kinase-based tumorigenesis. Mod. Pathol. 2008, 21, 96–104.
39. Nardi, V.; Song, Y.; Santamaria-Barria, J.A.; Cosper, A.K.; Lam, Q.; Faber, A.C.; Boland, G.M.; Yeap, B.Y.; Bergethon, K.; Scialabba, V.L.; et al. Activation of PI3K signaling in merkel cell carcinoma. Clin. Cancer Res. 2012, 18, 1227–1236.
40. Karakas, B.; Bachman, K.E.; Park, B.H. Mutation of the PI3KCA oncogene in human cancers. Br. J. Cancer 2006, 94, 455–459.
41. Lopez-Knowles, E.; Hernandez, S.; Malats, N.; Kogevinas, M.; Lloreta, J.; Carrato, A.; Tardon, A.; Serra, C.; Real, F.X. PIK3CA mutations are an early genetic alteration associated with FGFR3 mutations in superficial papillary bladder tumors. Cancer Res. 2006, 66, 7401–7404.
42. Hafner, C.; Hartmann, A.; Vogt, T. FGFR3 mutations in epidermal nevi and seborrheic keratoses: Lessons from urothelium and skin. J. Investig. Dermatol. 2007, 127, 1572–1573.
43. Hafner, C.; Houben, R.; Baeurle, A.; Ritter, C.; Schrama, D.; Landthaler, M.; Becker, J.C. Activation of the PI3K/AKT pathway in merkel cell carcinoma. PLoS One 2012, 7, e31255.
44. Van Gele, M.; Leonard, J.H.; van Roy, N.; Cook, A.L.; de Paepe, A.; Speleman, F. Frequent allelic loss at 10q23 but low incidence of pten mutations in merkel cell carcinoma. Int. J. Cancer 2001, 92, 409–413.
45. Samlowski, W.E.; Moon, J.; Tuthill, R.J.; Heinrich, M.C.; Balzer-Haas, N.S.; Merl, S.A.; DeConti, R.C.; Thompson, J.A.; Witter, M.T.; Flaherty, L.E.; et al. A phase II trial of imatinib mesylate in merkel cell carcinoma (neuroendocrine carcinoma of the skin): A southwest oncology group study (s0331). Am. J. Clin. Oncol. 2010, 33, 495–499.
46. National Cancer Institute. Prospective randomized phase II trial of pazopanib (NSC # 737754) versus placebo in patients with progressive carcinoid tumors. Available online: http://clinicaltrials.gov/show/nct01841736 (accessed on 1 June 2014).
47. Dana-farber Cancer Institute; Exelixis. Cabozantinib in recurrent/metastatic Merkel cell carcinoma. Available online: http://clinicaltrials.gov/show/nct02036476 (accessed on 1 June 2014).
48. National Cancer Institute. Nelfinavir in treating patients with metastatic, refractory, or recurrent solid tumors. Available online: http://clinicaltrials.gov/show/nct00436735 (accessed on 1 June 2014).
49. National Cancer Institute. Phase I study of anti-igf-1r monoclonal antibody, Imc-a12, and mtor inhibitor, everolimus, in advanced low to intermediate grade neuroendocrine carcinoma. Available online: http://clinicaltrials.gov/show/nct01204476 (accessed on 1 June 2014).
50. National Cancer Institute. A Phase I trial of the mtor inhibitor Rad001 in combination with VEGF receptor tyrosine kinase inhibitor ptk787/zk 222584 in patients with advanced solid tumors. Available online: http://clinicaltrials.GOV/show/nct00655655 (accessed on 1 June 2014).
51. Pfizer; University of Southern California. Phase I clinical trial of temsirolimus and vinorelbine in advanced solid tumors. Available online: http://clinicaltrials.gov/show/nct01155258 (accessed on 1 June 2014).
52. National Cancer Institute. A phase II trial of sti-571/imatinib (Gleevec®) (Nsc-716051) in neuroendocrine carcinoma of the skin (Merkel Cell Carcinoma). Available online: http://clinicaltrials.gov/show/nct00068783 (accessed on 1 June 2014).

53. Carson, H.J.; Lueck, N.E.; Horten, B.C. Comparison of mutant and wild-type p53 proteins in merkel cell carcinoma. Clin. Diagn. Lab. Immunol. 2000, 7, 326.

54. Lill, C.; Schneider, S.; Iten, C.B.; Loewe, R.; Houben, R.; Halbauer, D.; Heiduschka, G.; Brunner, M.; Thurnher, D. P53 mutation is a rare event in merkel cell carcinoma of the head and neck. Eur. Arch. Otorhinolaryngol. 2011, 268, 1639–1646.

55. Waltari, M.; Sihto, H.; Kukko, H.; Koljonen, V.; Sankila, R.; Bohling, T.; Joensuu, H. Association of merkel cell polyomavirus infection with tumor p53, KIT, stem cell factor, PDGFR-alpha and survival in merkel cell carcinoma. Int. J. Cancer 2011, 129, 619–628.

56. Lassacher, A.; Heitzer, E.; Kerl, H.; Wolf, P. p14ARF hypermethylation is common but INK4a-ARF locus or p53 mutations are rare in merkel cell carcinoma. J. Investig. Dermatol. 2008, 128, 1788–1796.

57. Van Gele, M.; Kaghad, M.; Leonard, J.H.; van Roy, N.; Naeyaert, J.M.; Geerts, M.L.; van Belle, S.; Cocquyt, V.; Bridge, J.; Sciot, R.; et al. Mutation analysis of p73 and tp53 in merkel cell carcinoma. Br. J. Cancer 2000, 82, 823–826.

58. Harris, C.C.; Hollstein, M. Clinical implications of the p53 tumor-suppressor gene. N. Engl. J. Med. 1993, 329, 1318–1327.

59. Momand, J.; Zambetti, G.P.; Olson, D.C.; George, D.; Levine, A.J. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 1992, 69, 1237–1245.

60. Oliner, J.D.; Kinzler, K.W.; Meltzer, P.S.; George, D.L.; Vogelstein, B. Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature 1992, 358, 80–83.

61. Houben, R.; Dreher, C.; Angermeyer, S.; Borst, A.; Utikal, J.; Haferkamp, S.; Peitsch, W.K.; Schrama, D.; Hesbacher, S. Mechanisms of p53 restriction in merkel cell carcinoma cells are independent of the merkel cell polyoma virus T antigens. J. Investig. Dermatol. 2013, 133, 2453–2460.

62. Leonard, J.H.; Hayard, N. Loss of heterozygosity of chromosome 13 in merkel cell carcinoma. Genes Chromosomes Cancer 1997, 20, 93–97.

63. Cimino, P.J.; Robirds, D.H.; Tripp, S.R.; Pfeifer, J.D.; Abel, H.J.; Duncavage, E.J. Retinoblastoma gene mutations detected by whole exome sequencing of merkel cell carcinoma. Mod. Pathol. 2014, 27, 1073–1087.

64. Larramendy, M.L.; Koljonen, V.; Bohling, T.; Tukiainen, E.; Knuutila, S. Recurrent DNA copy number changes revealed by comparative genomic hybridization in primary merkel cell carcinomas. Mod. Pathol. 2004, 17, 561–567.

65. Harle, M.; Arens, N.; Moll, I.; Back, W.; Schulz, T.; Scherthan, H. Comparative genomic hybridization (cgh) discloses chromosomal and subchromosomal copy number changes in merkel cell carcinomas. J. Cutan. Pathol. 1996, 23, 391–397.
66. Van Gele, M.; Leonard, J.H.; van Roy, N.; van Limbergen, H.; van Belle, S.; Cocquyt, V.; Salwen, H.; de Paepe, A.; Speleman, F. Combined karyotyping, CGH and M-FISH analysis allows detailed characterization of unidentified chromosomal rearrangements in merkel cell carcinoma. *Int. J. Cancer* 2002, 101, 137–145.

67. Paulson, K.G.; Lemos, B.D.; Feng, B.; Jaimes, N.; Penas, P.F.; Bi, X.; Maher, E.; Cohen, L.; Leonard, J.H.; Granter, S.R.; *et al.* Array-CGH reveals recurrent genomic changes in merkel cell carcinoma including amplification of L-Myc. *J. Investig. Dermatol.* 2009, 129, 1547–1555.

68. Vortmeyer, A.O.; Merino, M.J.; Boni, R.; Liotta, L.A.; Cavazzana, A.; Zhuang, Z. Genetic changes associated with primary merkel cell carcinoma. *Am. J. Clin. Pathol.* 1998, 109, 565–570.

69. Harnett, P.R.; Kearsley, J.H.; Hayward, N.K.; Dracopoli, N.C.; Keeford, R.F. Loss of allelic heterozygosity on distal chromosome 1p in merkel cell carcinoma. A marker of neural crest origins? *Cancer Genet. Cytogenet.* 1991, 54, 109–113.

70. Van Gele, M.; Speleman, F.; Vandesompele, J.; van Roy, N.; Leonard, J.H. Characteristic pattern of chromosomal gains and losses in merkel cell carcinoma detected by comparative genomic hybridization. *Cancer Res.* 1998, 58, 1503–1508.

71. Leonard, J.H.; Williams, G.; Walters, M.K.; Nancarrow, D.J.; Rabbitts, P.H. Deletion mapping of the short arm of chromosome 3 in merkel cell carcinoma. *Genes Chromosomes Cancer* 1996, 15, 102–107.

72. Gancberg, D.; Feoli, F.; Hamels, J.; de Saint-Aubain, N.; Andre, J.; Rouas, G.; Verhest, A.; Larsimont, D. Trisomy 6 in merkel cell carcinoma: A recurrent chromosomal aberration. *Histopathology* 2000, 37, 445–451.

73. Vasuri, F.; Magrini, E.; Foschini, M.P.; Eusebi, V. Trisomy of chromosome 6 in merkel cell carcinoma within lymph nodes. *Virchows Arch.* 2008, 452, 559–563.

74. Suciu, V.; Botan, E.; Valent, A.; Chami, L.; Spatz, A.; Vielh, P. The potential contribution of fluorescent *in situ* hybridization analysis to the cytopathological diagnosis of merkel cell carcinoma. *Cytopathology* 2008, 19, 48–51.

75. Sandbrink, F.; Muller, L.; Fiebig, H.H.; Kovacs, G. Short communication: Deletion 7q, trisomy 6 and 11 in a case of merkel-cell carcinoma. *Cancer Genet. Cytogenet.* 1988, 33, 305–309.

76. Shabtai, F.; Sternberg, A.; Klar, D.; Reiss, R.; Halbrecht, I. Involvement of chromosome 22 in a merkel cell carcinoma in a patient with a previous meningioma. *Cancer Genet. Cytogenet.* 1989, 38, 43–48.

77. Xie, H.; Lee, L.; Caramuta, S.; Hoog, A.; Browaldh, N.; Bjornhagen, V.; Larsson, C.; Lui, W.O. Microrna expression patterns related to merkel cell polyomavirus infection in human merkel cell carcinoma. *J. Investig. Dermatol.* 2014, 134, 507–517.

78. Boll, K.; Reiche, K.; Kasack, K.; Morbt, N.; Kretzschmar, A.K.; Tomm, J.M.; Verhaegh, G.; Schalken, J.; von Bergen, M.; Horn, F.; *et al.* Mir-130a, mir-203 and mir-205 jointly repress key oncogenic pathways and are downregulated in prostate carcinoma. *Oncogene* 2013, 32, 277–285.

79. Chiang, Y.; Song, Y.; Wang, Z.; Chen, Y.; Yue, Z.; Xu, H.; Xing, C.; Liu, Z. Aberrant expression of mir-203 and its clinical significance in gastric and colorectal cancers. *J. Gastrointest. Surg.* 2011, 15, 63–70.
80. Jin, J.; Deng, J.; Wang, F.; Xia, X.; Qiu, T.; Lu, W.; Li, X.; Zhang, H.; Gu, X.; Liu, Y.; et al. The expression and function of microrna-203 in lung cancer. *Tumour Biol.* **2013**, *34*, 349–357.

81. Diao, Y.; Guo, X.; Jiang, L.; Wang, G.; Zhang, C.; Wan, J.; Jin, Y.; Wu, Z. Mir-203, a tumor suppressor frequently down-regulated by promoter hypermethylation in rhabdomyosarcoma. *J. Biol. Chem.* **2014**, *289*, 529–539.

82. Knapp, C.F.; Sayegh, Z.; Schell, M.J.; Rawal, B.; Ochoa, T.; Sondak, V.K.; Messina, J.L. Expression of cxcr4, e-cadherin, bcl-2, and survivin in merkel cell carcinoma: An immunohistochemical study using a tissue microarray. *Am. J. Dermatopathol.* **2012**, *34*, 592–596.

83. Dresang, L.R.; Guastafierro, A.; Arora, R.; Normolle, D.; Chang, Y.; Moore, P.S. Response of merkel cell polyomavirus-positive merkel cell carcinoma xenografts to a survivin inhibitor. *PLoS One* **2013**, *8*, e80543.

84. Ning, M.S.; Kim, A.S.; Prasad, N.; Levy, S.E.; Zhang, H.; Andl, T. Characterization of the merkel cell carcinoma mirnome. *J. Skin Cancer* **2014**, doi:10.1155/2014/289548.

85. Banzhaf-Strathmann, J.; Edbauer, D. Good guy or bad guy: The opposing roles of microrna 125b in cancer. *Cell Commun. Signal.* **2014**, doi:10.1186/1478-811X-12-30.

86. Segura, M.F.; Hanniford, D.; Menendez, S.; Reavie, L.; Zou, X.; Alvarez-Diaz, S.; Zakrzewski, J.; Blochin, E.; Rose, A.; Bogunovic, D., et al. Aberrant mir-182 expression promotes melanoma metastasis by repressing foxo3 and microphthalmia-associated transcription factor. *Proc. Natl. Acad. Sci. USA* **2009**, *106*, 1814–1819.

87. Swick, B.L.; Ravdel, L.; Fitzpatrick, J.E.; Robinson, W.A. Merkel cell carcinoma: Evaluation of kit (cd117) expression and failure to demonstrate activating mutations in the c-kit proto-oncogene—Implications for treatment with imatinib mesylate. *J. Cutan. Pathol.* **2007**, *34*, 324–329.

88. Liu, S.; Daa, T.; Kashima, K.; Kondoh, Y.; Yokoyama, S. The wnt-signaling pathway is not implicated in tumorigenesis of merkel cell carcinoma. *J. Cutan. Pathol.* **2007**, *34*, 22–26.

89. Lill, C.; Schneider, S.; Ghanim, B.; Brunner, M.; Heiduschka, G.; Loewe, R.; Thurnher, D. Expression of beta-catenin and cyclin d1 in merkel cell carcinomas of the head and neck. *Wien. Klin. Wochenschr.* **2013**, *125*, 501–507.

90. Worda, M.; Sreevidya, C.S.; Ananthaswamy, H.N.; Cerroni, L.; Kerl, H.; Wolf, P. T1796a braf mutation is absent in merkel cell carcinoma. *Br. J. Dermatol.* **2005**, *153*, 229–232.

91. Houben, R.; Michel, B.; Vetter-Kauczok, C.S.; Pföhler, C.; Laetsch, B.; Wolter, M.D.; Leonard, J.H.; Trefzer, U.; Ugurel, S.; Schrama, D.; et al. Absence of classical map kinase pathway signalling in merkel cell carcinoma. *J. Investig. Dermatol.* **2006**, *126*, 1135–1142.

92. Filtenborg-Barnkob, B.E.; Bzorek, M. Expression of anaplastic lymphoma kinase in merkel cell carcinomas. *Hum. Pathol.* **2013**, *44*, 1656–1664.

93. Nagahama, J.; Daa, T.; Yada, N.; Kashima, K.; Fujiwara, S.; Saikawa, T.; Yokoyama, S. Tyrosine kinase receptor ron and its ligand msp in merkel cell carcinoma. *Pathol. Res. Pract.* **2011**, *207*, 463–467.

94. Panelos, J.; Batistatou, A.; Paglierani, M.; Zioga, A.; Maio, V.; Santi, R.; Pimpinelli, N.; de Giorgi, V.; Santucci, M.; Massi, D.; et al. Expression of notch-1 and alteration of the e-cadherin/beta-catenin cell adhesion complex are observed in primary cutaneous neuroendocrine carcinoma (merkel cell carcinoma). *Mod. Pathol.* **2009**, *22*, 959–968.
95. Sihto, H.; Kukko, H.; Koljonen, V.; Sankila, R.; Bohling, T.; Joensuu, H. Merkel cell polyomavirus infection, large T antigen, retinoblastoma protein and outcome in merkel cell carcinoma. *Clin. Cancer Res.* **2011**, *17*, 4806–4813.

96. Paulson, K.G.; Carter, J.J.; Johnson, L.G.; Cahill, K.W.; Iyer, J.G.; Schrama, D.; Becker, J.C.; Madeleine, M.M.; Nghiem, P.; Galloway, D.A.; *et al.* Antibodies to merkel cell polyomavirus T antigen oncoproteins reflect tumor burden in merkel cell carcinoma patients. *Cancer Res.* **2010**, *70*, 8388–8397.

97. Touze, A.; le Bidre, E.; Laude, H.; Fleury, M.J.; Cazal, R.; Arnold, F.; Carlotti, A.; Maubec, E.; Aubin, F.; Avril, M.F.; *et al.* High levels of antibodies against merkel cell polyomavirus identify a subset of patients with merkel cell carcinoma with better clinical outcome. *J. Clin. Oncol.* **2011**, *29*, 1612–1619.

98. Asioli, S.; Righi, A.; de Biase, D.; Morandi, L.; Caliendo, V.; Picciotto, F.; Macripo, G.; Maletta, F.; di Cantogno, L.V.; Chiusa, L.; *et al.* Expression of p63 is the sole independent marker of aggressiveness in localised (stage I-II) merkel cell carcinomas. *Mod. Pathol.* **2011**, *24*, 1451–1461.

99. Stetsenko, G.Y.; Malekirad, J.; Paulson, K.G.; Iyer, J.G.; Thibodeau, R.M.; Nagase, K.; Schmidt, M.; Storer, B.E.; Argenyi, Z.B.; Nghiem, P.; *et al.* P63 expression in merkel cell carcinoma predicts poorer survival yet may have limited clinical utility. *Am. J. Clin. Pathol.* **2013**, *140*, 838–844.

100. Lim, C.S.; Whalley, D.; Haydu, L.E.; Murali, R.; Tippett, J.; Thompson, J.F.; Hruby, G.; Scolyer, R.A. Increasing tumor thickness is associated with recurrence and poorer survival in patients with merkel cell carcinoma. *Ann. Surg. Oncol.* **2012**, *19*, 3325–3334.

101. Llombart, B.; Monteagudo, C.; Lopez-Guerrero, J.A.; Carda, C.; Jorda, E.; Sammartin, O.; Almenar, S.; Molina, I.; Martin, J.M.; Llombart-Bosch, A.; *et al.* Clinicopathological and immunohistochemical analysis of 20 cases of merkel cell carcinoma in search of prognostic markers. *Histopathology* **2005**, *46*, 622–634.

102. Kurzen, H.; Kaul, S.; Egner, U.; Deichmann, M.; Hartschuh, W. Expression of muc 1 and ep-cam in merkel cell carcinomas: Implications for immunotherapy. *Arch. Dermatol. Res.* **2003**, *295*, 146–154.

103. Koljonen, V.; Jahkola, T.; Tukiainen, E.; Granroth, G.; Haglund, C.; Bohling, T. Tenascin-c in primary merkel cell carcinoma. *J. Clin. Pathol.* **2005**, *58*, 297–300.

104. Brunner, M.; Thurnher, D.; Pammer, J.; Heiduschka, G.; Petzelbauer, P.; Schmid, C.; Schneider, S.; Erovic, B.M. Expression of hedgehog signaling molecules in merkel cell carcinoma. *Head Neck* **2010**, *32*, 333–340.

105. Fernandez-Figueras, M.T.; Puig, L.; Musulen, E.; Gilaberte, M.; Lerma, E.; Serrano, S.; Ferrandiz, C.; Ariza, A. Expression profiles associated with aggressive behavior in merkel cell carcinoma. *Mod. Pathol.* **2007**, *20*, 90–101.

106. Lill, C.; Schneider, S.; Pammer, J.; Loewe, R.; Gedlicka, W.; Houben, R.; Heiduschka, G.; Brunner, M.; Thurnher, D. Significant correlation of peptidyl-prolyl isomerase overexpression in merkel cell carcinoma with overall survival of patients. *Head Neck* **2011**, *33*, 1294–1300.
107. Koljonen, V.; Haglund, C.; Tukiainen, E.; Bohling, T. Neuroendocrine differentiation in primary merkel cell carcinoma—Possible prognostic significance. *Anticancer Res.* **2005**, *25*, 853–858.